NovaSight is a growing MedTech company dedicated to revolutionizing pediatric vision care through advanced technology and bringing it into the digital age. Founded in 2016, NovaSight has experienced rapid growth by delivering complete end-to-end eye tracking-based solutions for accurate diagnostic, treatment and prevention of early vision disorders.
NovaSight’s flagship product CureSight™, is an eye tracking-based device for the treatment of amblyopia intended to replace traditional eye patching. The EyeSwift®PRO system is a comprehensive vision diagnostics device that accurately and objectively screens for multiple vision impairments within seconds.
The company’s current development and clinical focus is directed towards TrackSight®, a SaaS application for myopia (short-sightedness) control, using AI-based eye tracking technology, with the objective of providing an affordable and accessible solution to help combat the myopia global epidemic. TrackSight is intended to run on consumer electronic devices such as tablets and laptops and eye tracking is done through the device’s integrated cameras.
The patented concept behind TrackSight, is digitizing the principles of “Myopic Blur” and “Contrast Reduction” of the proven myopia control glasses to run on any device and any content both local and online.
NovaSight’s degradation algorithm simulates a combination of contrast reduction and myopic blur technologies. The peripheral image is broken into its basic RGB components, and each image is blurred by a different amount and to a different contrast reduction to create our proprietary chromatic blur technology
Blurring is done in real-time through high-performance image processing at the device’s GPU level, allowing for excellent performance, transparent to the user
A center view image of ~6º is kept sharp while the periphery of the screen is being degraded by a combination of blur and contrast reduction. TrackSight addresses the ‘sweet spot” of retinal sensitivity which lies between 6º to 10º and typically missed by myopia control spectacle lenses. At the same time, the field of view is dynamically responsive to the distance to keep a constant angular field of view
TrackSight showed promising clinical results of the transient axial length response in initial proof of concept studies on both children and young adults in Israel and China. Consequently, the company is planning a multi-center clinical validation through a randomized control pivotal study with 200-300 pre-myopic children ages 5 to 10 in China, Israel, Singapore, US.
TrackSight could be potentially marketed as a standalone solution for pre-myopic children, or as a combination therapy with drugs or optical therapy following Myopia onset. Vision health features of distance tracking, dry eye warnings and eye fatigue warnings will be developed as a second step.